A phase 3 randomized study of pembrolizumab (Pembro) plus pomalidomide (Pom) and dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-183.

被引：9
|
作者：
Mateos, Maria-Victoria
Blacklock, Hilary
Schjesvold, Fredrik
Rocafiguera, Albert Oriol
Simpson, David
George, Anupkumar
Goldschmidt, Hartmut
Larocca, Alessandra
Sherbenou, Daniel Wayne
Avivi, Irit
Iida, Shinsuke
Matsumoto, Morio
Usmani, Saad Zafar
Jagannath, Sundar
Rodriguez-Otero, Paula
Kher, Uma
Farooqui, Mohammed Z. H.
Liao, Jason
Marinello, Patricia
Lonial, Sagar
机构：
[1] Univ Salamanca Hosp, Salamanca, Spain
[2] Middlemore Hosp, Auckland, New Zealand
[3] Oslo Univ Sykehus Rikshosp Postboks, Oslo, Norway
[4] Hosp Univ Germans Trias Pujol, Barcelona, Spain
[5] North Shore Hosp, Auckland, New Zealand
[6] Wellington Blood & Canc Ctr, Wellington, New Zealand
[7] Heidelberg Univ, Heidelberg, Germany
[8] Univ Torino, Div Hematol, Myeloma Unit, Turin, Italy
[9] Univ Colorado, Canc Ctr, Denver, CO USA
[10] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel
[11] Nagoya City Univ, Grad Sch Med Sci, Nagoya, Aichi, Japan
[12] Natl Hosp Org, Shibukawa Med Ctr, Shibukawa, Gunma, Japan
[13] Levine Canc Inst, Carolinas Healthcare Syst, Charlotte, NC USA
[14] Mt Sinai Med Ctr, New York, NY 10029 USA
[15] Clin Univ Navarra, Pamplona, Spain
[16] Merck & Co Inc, Kenilworth, NJ USA
[17] Emory Univ, Winship Canc Inst, Atlanta, GA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.8021
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8021
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Pembrolizumab in Combination with Pomalidomide and Dexamethasone (PEMBRO/POM/DEX) for Pomalidomide Exposed Relapsed or Refractory Multiple Myeloma
    Wilson, Lilly
    Cohen, Adam D.
    Weiss, Brendan M.
    Vogl, Dan T.
    Garfall, Alfred L.
    Capozzi, Donna L.
    Mangan, Patricia
    Sanchez, Mary
    Erb, Colleen
    Stadtmauer, Edward
    [J]. BLOOD, 2016, 128 (22)
  • [2] A PHASE IB STUDY OF ISATUXIMAB PLUS POMALIDOMIDE (POM) AND DEXAMETHASONE (DEX) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Mikhael, J.
    Richardson, P.
    Usmani, S.
    Raje, N.
    Bensinger, W.
    Kanagavel, D.
    Gao, L.
    Ziti-ljajic, S.
    Anderson, K.
    [J]. HAEMATOLOGICA, 2017, 102 : 168 - 168
  • [3] Pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma (rrMM): Randomized, phase 3 KEYNOTE-183 study
    Ocio, E. M.
    Shah, J.
    Jagannath, S.
    Mateos, M-V
    Palumbo, A.
    Kher, U.
    Marinello, P.
    San Miguel, J.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [4] Updated Results from a Phase Ib Study of Isatuximab Plus Pomalidomide (Pom) and Dexamethasone (dex) in Relapsed/Refractory Multiple Myeloma (RRMM)
    Richardson, Paul G.
    Mikhael, Joseph
    Usmani, Saad Z.
    Raje, Noopur
    Bensinger, William
    Kanagavel, Dheepak
    Gao, Lei
    Ziti-Ljajic, Samira
    Anderson, Kenneth C.
    [J]. BLOOD, 2017, 130
  • [5] Final results of a phase Ib study of isatuximab (ISA) plus pomalidomide (Pom) and dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM).
    Mikhael, Joseph
    Richardson, Paul G.
    Usmani, Saad Zafar
    Raje, Noopur S.
    Bensinger, William
    Dubin, Franck
    Liu, Qianying
    Vitse, Olivier
    Anderson, Kenneth Carl
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] A multicenter, randomized, phase 3 study of pomalidomide and dexamethasone (Pom-dex) with or without daratumumab in patients with relapsed or refractory multiple myeloma (RRMM): APOLLO
    Terpos, E.
    Dimopoulos, M. A.
    Kastritis, E.
    Schecter, J. M.
    Ukropec, J.
    Smith, E.
    Sonneveld, P.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [7] KEYNOTE-183: A randomized, open-label phase 3 study of pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma (rrMM).
    Shah, Jatin J.
    Jagannath, Sundar
    Mateos, Maria-Victoria
    Palumbo, Antonio
    Kher, Uma
    Marinello, Patricia Maria
    San Miguel, Jesus
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM)
    Badros, Ashraf Z.
    Hyjek, Elizabeth
    Ma, Ning
    Lesokhin, Alexander M.
    Rapoport, Aaron P.
    Kocoglu, Mehmet H.
    Lederer, Emily
    Philip, Sunita
    Lesho, Patricia
    Johnson, Ashlee
    Dell, Cameron
    Goloubeva, Olga
    Singh, Zeba
    [J]. BLOOD, 2016, 128 (22)
  • [9] Preliminary Results From a Phase Ib Study of Isatuximab in Combination with Pomalidomide (Pom) and Dexamethasone (Dex) in Relapsed and Refractory Multiple Myeloma (RRMM)
    Richardson, Paul
    Mikhael, Joseph
    Usmani, Saad
    Raje, Napoor
    Bensinger, William
    Campana, Frank
    Gao, Lei
    Dubin, Franck
    Wack, Claudine
    Anderson, Kenneth C.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E16 - E17
  • [10] Pembrolizumab plus pomalidomide and dexamethasone for relapsed or refractory multiple myeloma (KEYNOTE-183): subgroup analysis in Japanese patients
    Morio Matsumoto
    Kenshi Suzuki
    Junya Kuroda
    Masafumi Taniwaki
    Kazutaka Sunami
    Hiroshi Kosugi
    Kiyoshi Ando
    Dai Maruyama
    Kensei Tobinai
    Uma Kher
    Mohammed Farooqui
    Jason Liao
    Patricia Marinello
    Kenji Matsuda
    Yasuhiro Koh
    Takashi Shimamoto
    Shinsuke Iida
    [J]. International Journal of Hematology, 2021, 113 : 777 - 784
12345